Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trial therapy demonstrates clinical benefit, manageable safety in patients with R/R MCL

Publish date:: March 18, 2020

Key clinical point: With more than 1 y follow-up, KTE-X19 demonstrated a significant and durable clinical benefit, with a manageable safety profile.

Major finding: Investigator-assessed overall response rate was 86% with a clinical response rate of 57%.

Study details: Assessment of 20 patients with R/R MCL who received KTE-X19, an autologous anti-CD19 CAR T cell therapy.

Disclosures: The Zuma-2 study was funded by Kite, a Gilead Company. There were no author disclosures indicated.

Citation:

Wang M et al. Biol Blood Marrow Transplant. 2020 26:S1-S7.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Mantle Cell Lymphoma

Survey quantifies COVID-19’s impact on oncology,

Angiogenesis, SOX11 expression in MCL positively correlate to increased inflammatory infiltrate,

Benefit of allo SCT for MCL offset by increased risk of mortality, GVHD,

RB/RC induction followed by ASCT achieved high rates of durable MCL remissions,

Case report shows MCL presenting as cryoglobulinemic vasculitis,